Samarkand Group plc
| Symbol | Ccy Code | Bid | Ask | Mid | Previous Close | Volume | Last Traded |
|---|---|---|---|---|---|---|---|
| SMK | GBX | 160 | 170 | 165 | 165 | 8396 | 21.10.21 |
MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.
Financial Information
| Last results date: 30.11.20 | |
|---|---|
| Enterprise Value | - |
| EV/EBITDA | - |
| EV/EBIT | - |
| PE Ratio | - |
| PEG | - |
| Dividend Yield | - |
| Free Cash Yield | - |
Click here to download a glossary of terms.
All data provided by Fregnan.
| 31.03.19 (£'000) |
31.03.20 (£'000) |
30.11.20 (£'000) |
|
|---|---|---|---|
| Income Statement | |||
| Revenue | 4,482 | 6,844 | 16,016 |
| Operating Income (EBIT) | (1,154) | (1,142) | 2,115 |
| Net Income | (1,311) | (1,388) | 1,667 |
| Balance Sheet | |||
| Cash | 271 | 573 | 1,232 |
| Total Debt | 4,746 | 6,462 | 5,727 |
| Total Liabilities | 5,855 | 8,609 | 9,134 |
| Total Equity | (1,678) | (3,081) | (1,418) |
| Operating Margin | (25.74)% | (16.69)% | 13.20% |
| EPS - Basic | (741.90)p | (785.26)p | 943.39p |
| EPS - Growth | - | 5.84% | (220.14)% |
| Dividend Per Share | - | - | - |
| Average Shares Outstanding | 0.18m | 0.18m | 0.18m |
| ROA | - | (28.59%) | 25.17% |
| ROCE | - | (266.25%) | 585.68% |
| ROE | - | 58.31% | (74.10%) |
Click here to download a glossary of terms.
All data provided by Fregnan.
| 31.03.19 (£'000) |
31.03.20 (£'000) |
30.11.20 (£'000) |
|
|---|---|---|---|
| Revenue | 4,482 | 6,844 | 16,016 |
| Cost of Revenue | 2,927 | 3,563 | 6,903 |
| Depreciation & Amortisation | 111 | 313 | 318 |
| Gross Profit | 1,444 | 2,968 | 8,795 |
| Other Operating Expenses | 2,598 | 4,111 | 6,680 |
| Operating Income (EBIT) | (1,154) | (1,142) | 2,115 |
| Net Interest Expense | 153 | 296 | 245 |
| Unusual Expense (incl. Exceptionals) | - | - | 102 |
| Non-Operating Expense | 3 | 6 | 0 |
| Profit (pre-tax) | (1,304) | (1,432) | 1,768 |
| Taxation | (7) | 44 | (101) |
| Other Expenses and Minortity Interest | - | - | - |
| Net Income | (1,311) | (1,388) | 1,667 |
Click here to download a glossary of terms.
All data provided by Fregnan.
| 31.03.19 (£'000) |
31.03.20 (£'000) |
30.11.20 (£'000) |
|
|---|---|---|---|
| Cash from Operations | (1,356) | (563) | 2,027 |
| Cash from Investing | (271) | (587) | (416) |
| Cash from Financing | 1,482 | 1,454 | (947) |
| Other Miscellaneous | - | - | - |
| Net Cash Flow | (145) | 303 | 664 |
Click here to download a glossary of terms.
All data provided by Fregnan.
| 31.03.19 (£'000) |
31.03.20 (£'000) |
30.11.20 (£'000) |
|
|---|---|---|---|
| Current Assets | 2,164 | 3,238 | 5,299 |
| Non-Current Assets | 2,013 | 2,291 | 2,417 |
| Total Assets | 4,177 | 5,528 | 7,716 |
| Current Liabilities | 3,212 | 5,635 | 6,887 |
| Non-Current Liabilities | 2,643 | 2,974 | 2,247 |
| Total Liabilities | 5,855 | 8,609 | 9,134 |
| Net Assets | (1,678) | (3,081) | (1,418) |
| Total Equity | (1,678) | (3,081) | (1,418) |
Click here to download a glossary of terms.
All data provided by Fregnan.
Address
Business Address
Samarkand Group plc, Unit 13 & 14, Nelson Trading Estate, The Path, London, SW19 3BL, United Kingdom.
Email: info@samarkand.global
Phone: 020 3740 3933
Registered Address
Unit 13 & 14, Nelson Trading Estate, The Path, London, SW19 3BL, United Kingdom.
Contacts
Corporate Adviser
VSA Capital Ltd, New Liverpool House 15 Eldon Street, London, United Kingdom.
Phone: 020 3005 5000
Registrar
Neville Registrars Limited , Neville House,Steelpark Road, Halesowen, West Midlands, B62 8HD, United Kingdom.
Email: info@nevilleregistrars.co.uk
Phone: +44 (0) 121 585 1131
Research
I'm sorry there is no research for this company.